Escalating Dose Study in Healthy Volunteers With SEN0014196

Phase 1 Completed 88 enrolled Siena Biotech S.p.A.

RandomizedSingle-groupTriple-blindTreatment

This is a trial in healthy volunteers to study the safety, tolerability and pharmacokinetics of single and multiple escalating doses of SEN0014196.

Evaluation	Drug	Modality	Dose	Route
Subject	SEN0014196	Unknown	5 mg	Oral
Subject	SEN0014196	Unknown	25 mg	Oral
Subject	SEN0014196	Unknown	75 mg	Oral
Subject	SEN0014196	Unknown	100 mg	Oral
Subject	SEN0014196	Unknown	150 mg	Oral
Subject	SEN0014196	Unknown	300 mg	Oral
Subject	SEN0014196	Unknown	600 mg	Oral